Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer
Completed · Phase 2
Conditions studied: Breast Cancer
In brief
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining erlotinib with docetaxel may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining erlotinib with docetaxel in treating patients who have stage IV or recurrent breast cancer.
Key facts
- Study ID
- NCT00054275
- Run by
- Paula Silverman, MD
- People needed
- 39
- Starts
- 2002-12-01
- Expected to finish
- 2012-11-01
- Last updated by the study team
- 2016-02-17
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center — Cleveland, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.